B of A Securities reiterated coverage on Kiniksa Pharmaceuticals with a new price target
$KNSA
Biotechnology: Pharmaceutical Preparations
Health Care
B of A Securities reiterated coverage of Kiniksa Pharmaceuticals with a rating of Buy and set a new price target of $34.00 from $37.00 previously